The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
FPLA Regulation - Agency Information Collection Activities; Proposed Collection; Comment Request; Extension
20051599: Manulife Financial Corporation; President and Fellows of Harvard College
20051594: Superior Plus Income Fund; Wellspring Capital Partners III, L.P.
20051590: Financiere F.L.; UNOVA, Inc.
20051573: J. Kent McNew; BP p.l.c.
20051572: American Electric Power Company, Inc.; Reliant Energy, Inc.
20051571: Illinois Tool Works Inc.; Kirtland Capital Partners III L.P.
20051557: Triad Hospitals, Inc.; Baptist Health System, Inc.
Sacane, Scott R., U.S. (for the FTC)
The complaint alleged that Scott R. Sacane, a Connecticut hedge fund manager, failed to comply with notification and waiting period requirements before making acquisitions of two companies through an investment fund that he controlled. Sacane eventually held more than 50 percent of the voting securities of Aksys Ltd. and more than $100 million of voting securities of Esperion Therapeutics, Inc., without complying with the HSR Act. Under the terms of a consent decree filed simultaneously with the suit, Sacane agreed to pay a civil penalty of $350,000 to settle the charges.
20051629: Omnicom Group Inc.; Ford Motor Company
20051619: Cendant Corporation; Wind Hotels Holdings Inc.
20051611: Argos Acquisition Pte. Ltd.; Agilent Technologies, Inc.
20051593: Sun Capital Partners IV, LP; Sterling Group Partners I, LP
20051540: Layne Christensen Company; Reynolds, Inc.
20051532: LifePoint Hospitals, Inc.; HCA Inc.
Telebrands Corp., TV Savings LLC, and Ajit Khubani, In the Matter of
Partners Health Network, Inc., In the Matter of
Novartis AG, In the Matter of (Eon Labs, Inc)
To resolve competitive concerns for three generic pharmaceuticals that arose from Novartis AG’s acquisition of Eon Labs, Inc., Novartis agreed to divest all the assets necessary to manufacture and market generic desipramine hydrochloride tablets, orphenadrine citrate extended release (ER) tablets, and rifampin oral capsules in the United States to Amide within 10 days of Novartis’s acquisition of Eon. Further, Novartis, through its Sandoz generic pharmaceuticals division, will supply Amide with orphenadrine citrate ER and desipramide hydrochloride tablets until Amide obtains FDA approval to manufacture the products itself, and will assist Amide in obtaining all necessary FDA approvals.